Daewoong launches GERD treatment Fexuclu in Philippines

The company exports its homegrown developed gastroesophageal reflux disease new drug overseas for the first time

Daewoong Pharmaceutical's Fexuclue
Daewoong Pharmaceutical's Fexuclue
In-hyuk Park 1
2023-08-01 17:38:30 hyuk@hankyung.com
Bio & Pharma

South Korea's Daewoong Pharmaceutical announced on Tuesday that it has launched the GERD treatment drug "Fexuclue" (active ingredient: Fexuprazan) in the Philippines.

With this launch in the Philippines, Daewoong Pharmaceutical has achieved its first overseas expansion of Fexuclue.

The local distribution and sales marketing of Fexuclue is managed by PNSV Asia, one of the companies under the SV More Group. SV More has been a collaborative partner handling sales and marketing for Daewoong's gastrointestinal products such as "Urusa," a liver function enhancer, and "Bearse," a digestive medicine, for over 10 years.

Daewoong Pharmaceutical began the development of Fexuclue in 2008 and finally released it last year as a potassium-competitive acid blocker (P-CAB). It has improved on the drawbacks of existing proton-pump inhibitor (PPI) drugs, such as slow onset of action, susceptibility to dietary influence and drug interactions.

According to the company, Fexuclue has the longest half-life among GERD treatments, lasting for 9 hours. Its extended efficacy is advantageous for improving symptoms like nighttime heartburn.

"Starting with the Philippines, we will continue to make significant inroads in the global GERD market and aim to achieve a global sales target of 1 trillion won ($780 million) by 2030," CEO of Daewoong Pharmaceutical Jeon Seng-Ho said. "We will secure additional indications and expand the drug's formulation for improved convenience in administration."

Write to In-hyuk Park at hyuk@hankyung.com
#Daewoong Pharmaceutical #GERD treatment drug #Fexuclue #Fexuprazan #PNSV Asia #SV More Group #P-CAB #PPI

Daewoong's Nabota exceeds 600,000 customers in US

Daewoong's Nabota exceeds 600,000 customers in US

South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum toxin developed by the company, has surpassed 600,000 members. The program, called Evolus Rewards, offers appointment reservations and benefits for N

HanAll, Daewoong to develop Parkinson's treatment with US partner

HanAll, Daewoong to develop Parkinson's treatment with US partner

South Korea's HanAll Biopharma Co. and Daewoong Pharmaceutical on Thursday said they concluded a contract with NurrOn Pharmaceuticals of the US on joint development of treatments for neurodegenerative diseases such as Parkinson's. The value of the deal was not disclosed.NurrOn was founded by

Daewoong Pharmaceutical’s cumulative tech exports exceed $870 mn

Daewoong Pharmaceutical’s cumulative tech exports exceed $870 mn

South Korea’s Daewoong Pharmaceutical said on Friday that it had concluded three technology export agreements for new drugs and new drug candidates as of May 2023. The total size of the technology exports is 1.16 trillion won ($870 million). The journey commenced in January with the

Daewoong Pharma to build third botulinum toxin plant for $746 mn

Daewoong Pharma to build third botulinum toxin plant for $746 mn

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cost of over 100 billion won ($746 million).The company on Tuesday said the facility will boost production by 13 million units to expand Nabota's bus

Daewoong wins approval for GERD treatment Fexuclu in Chile

Daewoong wins approval for GERD treatment Fexuclu in Chile

Daewoong's Fexuclue South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National Medicines Agency Department (ANAMED) within the Public Health Institute for its gastroesophageal reflux disease drug (GERD) Fex
(* comment hide *}